I förra veckan publicerade forskare den hittills största studien på psilocybin, ämnet som finns i magiska svampar, mot svårbehandlad depression. Ur studien:“Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression Psilocybin is being studied for use in treatment-resistant depression. RESULTSA total of 79 participants were in the 25-mg group, 75 in the 10-mg group, and 79 in the 1-mg group. In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.

Source: Dagens Nyheter November 08, 2022 11:04 UTC